Trial Information

Summary: CAMP Schizophrenia Study

The Schizophrenia Trials Network is currently conducting the CAMP (Comparison of Antipsychotics for Metabolic Problems) study, which is aimed at better understanding the risks and benefits associated with antipsychotic use, especially with regard to the physical health outcomes of people with psychotic disorders. It is designed for people with schizophrenia or schizoaffective disorder who may be considering a medication change because of weight gain, high cholesterol, or other health problems. All participants will receive a medication that is FDA-approved for people with schizophrenia and schizoaffective disorder. The study involves the atypical antipsychotics Zyprexa, Seroquel, or Risperdal.

To be included in the study, participants must:

• Have a diagnosis of schizophrenia or schizoaffective disorder, Be 18-65 years old, and Be stable on Zyprexa, Seroquel, or Risperdal
• Participants must not be pregnant or breastfeeding.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.